-
Mashup Score: 2
Anti-IL-1Ra autoantibodies were observed in a high proportion of patients with MIS-C and were specific to these patients. Generation of these autoantibodies might be triggered by an atypical, hyperphosphorylated isoform of IL-1Ra. These autoantibodies impair IL-1Ra bioactivity and might thus contribute to increased IL-1β-signalling in MIS-C.
Source: The Lancet RheumatologyCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0Long-awaited action on rare diseases - 2 year(s) ago
England’s first Rare Diseases Action Plan, published on Feb 28 to mark Rare Disease Day 2022, was met with a mixture of hope and apprehension. Hope that the many people who suffer from individual rare diseases will benefit from faster diagnosis and increased support, but apprehension that much of what is promised will be a struggle to deliver given the strained resources of the National Health…
Source: The Lancet RheumatologyCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0Evaluation of supported self-management in gout (GoutSMART): a randomised controlled feasibility trial - 2 year(s) ago
Supported self-management of gout results in substantially improved attainment of urate targets compared with usual care, and it is well tolerated. Larger trials will be needed to fully evaluate the clinical and cost-effectiveness of this approach.
Source: The Lancet RheumatologyCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 3The Lancet Rheumatology - 2 year(s) ago
Explore clinical research, expert reviews, and comment and opinion from The Lancet Rheumatology. A voice for rheumatology specialists worldwide
Source: www.thelancet.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0The Lancet Rheumatology - 2 year(s) ago
Explore clinical research, expert reviews, and comment and opinion from The Lancet Rheumatology. A voice for rheumatology specialists worldwide
Source: www.thelancet.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 2The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial - 2 year(s) ago
Secukinumab resulted in early, statistically significant, clinically meaningful, sustained improvements in PROs across all doses compared with placebo in patients with active psoriatic arthritis. These improvements were seen irrespective of previous TNF inhibitor use, in a post-hoc analysis. These results indicate that secukinumab provides comprehensive improvement for patients with psoriatic…
Source: The Lancet RheumatologyCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 6
Humoral responses following vaccination are impaired by specific immunosuppressants. After standard vaccination regimens, patients with immune-mediated inflammatory disorders taking most immunosuppressants show similar seroconversion to controls, although antibody titres might be moderately reduced. As neutralisation capacity and recall responses are also preserved in these patients, this is not…
Source: The Lancet RheumatologyCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0Research in Brief - 2 year(s) ago
Tofacitinib did not demonstrate non-inferiority to TNF inhibitors on the coprimary outcomes of major cardiovascular events (MACE) and cancer (excluding non-melanoma skin cancer) in patients with rheumatoid arthritis and elevated cardiovascular risk in the open-label, non-inferiority, ORAL Surveillance trial by Steven Ytterberg and colleagues. 4362 patients aged 50 years or older with active…
Source: The Lancet RheumatologyCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 3
Methotrexate plus leflunomide combination therapy results in greater improvement in disease activity according to PASDAS in patients with psoriatic arthritis. However, methotrexate plus leflunomide combination therapy is less well tolerated than methotrexate monotherapy.
Source: The Lancet RheumatologyCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 10Battling burnout - 2 year(s) ago
The future of global health care is at risk. The pandemic, along with overwhelming workloads and record waiting lists, has exacerbated existing barriers to ensuring the wellbeing of health-care workers, leading to fatigue, stress, and poor mental health. As a result, health-care workers are leaving their jobs in droves, citing exhaustion and burnout. What will it take to avert further crisis?
Source: The Lancet RheumatologyCategories: Latest Headlines, RheumatologyTweet
NEW RESEARCH—Autoantibodies against interleukin-1 receptor antagonist in multisystem inflammatory syndrome in children (#MISC): a multicentre, retrospective, cohort study https://t.co/5OlstYLcWr #LancetRheumatology https://t.co/4uXmopexzm